T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.82B |
| 2 |
Sea Limited
SE
|
+$1.38B |
| 3 |
Cisco
CSCO
|
+$1.16B |
| 4 |
Netflix
NFLX
|
+$1.14B |
| 5 |
Ingersoll Rand
IR
|
+$1.03B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.54B |
| 2 |
Amazon
AMZN
|
+$1.75B |
| 3 |
Amphenol
APH
|
+$1.65B |
| 4 |
KLA
KLAC
|
+$1.5B |
| 5 |
Xcel Energy
XEL
|
+$1.38B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.6% |
| 2 | Financials | 11.17% |
| 3 | Healthcare | 11.1% |
| 4 | Communication Services | 10.25% |
| 5 | Consumer Discretionary | 10.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
Immunocore
IMCR
$1.74B
| $27.7M | ﹤0.01% |
919,332
-49,452
| -5% | -$1.6M |
|
952
Five Below
FIVE
$11.4B
| $27.6M | ﹤0.01% |
120,979
+70,128
| +138% | +$14.7M |
|
953
Camtek
CAMT
$6.95B
| $27.6M | ﹤0.01% |
+182,230
| New | +$27.6M |
|
954
StoneCo
STNE
$2.65B
| $27.5M | ﹤0.01% |
1,947,595
-292,382
| -13% | -$4.49M |
|
|
BCAX
955
Bicara Therapeutics
BCAX
$1.86B
| $27.4M | ﹤0.01% |
1,376,198
-183,337
| -12% | -$3.16M |
|
956
Lennar Class A
LEN
$20.5B
| $27.3M | ﹤0.01% |
314,722
-12,545
| -4% | -$1.36M |
|
957
HF Sinclair
DINO
$16.4B
| $27.3M | ﹤0.01% |
437,955
+72,907
| +20% | +$3.95M |
|
958
Babcock & Wilcox
BW
$1.39B
| $27.2M | ﹤0.01% |
+1,853,633
| New | +$19.5M |
|
959
Alarm.com
ALRM
$2.68B
| $27.2M | ﹤0.01% |
629,489
-266,130
| -30% | -$12.7M |
|
960
Sprouts Farmers Market
SFM
$7.23B
| $27.2M | ﹤0.01% |
352,372
-92,929
| -21% | -$6.94M |
|
|
RAPP
961
Rapport Therapeutics
RAPP
$2.01B
| $27.1M | ﹤0.01% |
866,456
-15,153
| -2% | -$426K |
|
962
International Flavors & Fragrances
IFF
$19.6B
| $27.1M | ﹤0.01% |
373,663
-1,920
| -0.5% | -$141K |
|
963
T. Rowe Price
TROW
$25.4B
| $27M | ﹤0.01% |
300,012
-13,910
| -4% | -$1.35M |
|
964
Expeditors International
EXPD
$22.4B
| $27M | ﹤0.01% |
188,430
-10,151
| -5% | -$1.54M |
|
965
Vale
VALE
$62.6B
| $27M | ﹤0.01% |
1,696,209
+211,173
| +14% | +$3.3M |
|
966
Bunge Global
BG
$22.7B
| $27M | ﹤0.01% |
212,065
+8,630
| +4% | +$1M |
|
967
SBA Communications
SBAC
$18.3B
| $26.8M | ﹤0.01% |
155,849
-135,167
| -46% | -$25.3M |
|
|
HOLX
968
DELISTED
Hologic
HOLX
| $26.8M | ﹤0.01% |
353,877
-8,796
| -2% | -$661K |
|
969
Charter Communications
CHTR
$15.7B
| $26.7M | ﹤0.01% |
123,660
-1,473
| -1% | -$319K |
|
970
Noble Corp
NE
$6.86B
| $26.7M | ﹤0.01% |
543,475
+432,069
| +388% | +$17.7M |
|
971
Crane Co
CR
$13B
| $26.6M | ﹤0.01% |
155,623
-34,911
| -18% | -$6.7M |
|
972
T. Rowe Price US Equity Research ETF
TSPA
$4.17B
| $26.5M | ﹤0.01% |
648,407
| – | – |
|
|
GENB
973
Generate Biomedicines
GENB
$1.77B
| $26.4M | ﹤0.01% |
+2,109,633
| New | +$25.8M |
|
974
SSR Mining
SSRM
$5.46B
| $26.3M | ﹤0.01% |
893,320
+775,699
| +659% | +$20.6M |
|
|
LINE
975
Lineage Inc
LINE
$9.69B
| $26.3M | ﹤0.01% |
801,315
-65,138
| -8% | -$2.41M |
|
Similar funds
T. Rowe Price Associates's Q1 2026 Portfolio in Review
As of Q1 2026, T. Rowe Price Associates held 3,202 positions worth $865B, down 6.7% from $927B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
T. Rowe Price Associates's Q1 2026 filing shows 115 new, 2,022 increased, 804 reduced and 71 closed positions. Its largest new stake was Cenovus Energy: 23,907,299 shares worth $634M. The largest sale was Microsoft, an estimated $3.54B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q1 2026 buy was Cenovus Energy: 23,907,299 shares worth $634M.
- T. Rowe Price Associates added most to Advanced Micro Devices in Q1 2026, an estimated $1.82B increase.
- T. Rowe Price Associates's biggest Q1 2026 reduction was Microsoft, cutting an estimated $3.54B.
- T. Rowe Price Associates fully exited CyberArk in Q1 2026, selling an estimated $251M.
- T. Rowe Price Associates's ten largest holdings make up 34% of its $865B portfolio in Q1 2026.
- T. Rowe Price Associates opened 115 new positions and closed 71 in Q1 2026.
- T. Rowe Price Associates's portfolio value fell 6.7% quarter-over-quarter to $865B.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.